We show here that IGF2 is expressed in TSC2-null mouse embryo fibroblasts (MEFs) and in human LAM cells, but it is insensitive to rapamycin treatment, and thus, targeting its signaling pathway is a potentially novel LAM therapeutic avenue. Here, TSC2 is linked to lymphangioleiomyomatosis.